Amit Mehta
SlowingNamed in filings at Builders VCOn the current fund
- Board seats filed
- 4
Named in filings at Builders VCOn the current fund
all filings on record
last 24 months
from a verified or cited source
| PRESSURE HEMP | Not yet classified | — | None on file |
| Novascan | Not yet classified | April 2026 | None on file |
| Pathos AI | Biotech & pharma | October 2024 | NEA |
| Arpeggio Biosciences | Biotech & pharma | August 2022 | Venbio Global Strategic, Westlake Biopartners |
The company and date are what the SEC filing shows, not a statement of investment thesis. A partner can sit on a board for reasons that say nothing about what their firm funds today. The category is not a filing value: it is Lev’s own classification of each company, shown only when we found a specific, checkable source for it; otherwise it reads “Not yet classified.” “Also on the board from” names another tracked firm with a partner on the same board, both with a clean identity match. It is not a claim either firm led or co-led the round, and “None on file” means no other tracked firm’s partner shares this specific board seat, not that no one else invested. Sorted newest first by default; click a column to change it. Something wrong? Tell us.
Too few filings to infer a focus. 2 of 4 filed seats classified so far.